SLITRK2

Summary

SLITRK2 (SLIT and NTRK like family member 2, HGNC:13449) is a protein-coding gene on chromosome Xq27.3, encoding SLIT and NTRK-like protein 2 (Q9H156). It is involved in synaptogenesis and promotes excitatory synapse differentiation.

This gene encodes an integral membrane protein that contains two N-terminal leucine-rich repeats domains and contains C-terminal regions similar to neurotrophin receptors. The encoded protein may play a role in modulating neurite activity. Alternatively spliced transcript variants encoding the same protein have been described.

Source: NCBI Gene 84631 — RefSeq curated summary.

At a glance

• Gene–disease (curated): intellectual developmental disorder, X-linked 111 (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 2
• Clinical variants (ClinVar): 143 total — 2 likely-pathogenic
• Phenotypes (HPO): 24
• MANE Select transcript: NM_032539

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13449
Approved symbol	SLITRK2
Name	SLIT and NTRK like family member 2
Location	Xq27.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1854, CXorf2
Ensembl gene	ENSG00000185985
Ensembl biotype	protein_coding
OMIM	300561
Entrez	84631

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 14 protein_coding

ENST00000335565, ENST00000370490, ENST00000867861, ENST00000867862, ENST00000867863, ENST00000867864, ENST00000867865, ENST00000867866, ENST00000867867, ENST00000867868, ENST00000867869, ENST00000966678, ENST00000966679, ENST00000966680

RefSeq mRNA: 8 — MANE Select: NM_032539 NM_001144003, NM_001144004, NM_001144005, NM_001144006, NM_001144008, NM_001144009, NM_001144010, NM_032539

CCDS: CCDS14680

Canonical transcript exons

ENST00000335565 — 5 exons

Exon	Start	End
ENSE00001517261	145822005	145822153
ENSE00001517265	145822383	145829856
ENSE00001630476	145820474	145820536
ENSE00001678002	145821348	145821884
ENSE00001773254	145817829	145818026

Expression profiles

Bgee: expression breadth ubiquitous, 166 present calls, max score 86.08.

FANTOM5 (CAGE): breadth broad, TPM avg 7.5143 / max 651.2898, expressed in 365 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
197903	2.9128	153
197899	2.8132	319
197900	1.6124	245
197901	0.1759	85

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	86.08	gold quality
medial globus pallidus	UBERON:0002477	83.96	gold quality
caudate nucleus	UBERON:0001873	81.54	gold quality
nucleus accumbens	UBERON:0001882	81.53	gold quality
ganglionic eminence	UBERON:0004023	80.86	gold quality
globus pallidus	UBERON:0001875	80.85	gold quality
middle temporal gyrus	UBERON:0002771	80.04	gold quality
amygdala	UBERON:0001876	79.92	gold quality
right frontal lobe	UBERON:0002810	79.51	gold quality
putamen	UBERON:0001874	78.97	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	78.91	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	78.30	gold quality
Brodmann (1909) area 9	UBERON:0013540	78.22	gold quality
prefrontal cortex	UBERON:0000451	78.07	gold quality
cingulate cortex	UBERON:0003027	77.98	gold quality
anterior cingulate cortex	UBERON:0009835	77.71	gold quality
sural nerve	UBERON:0015488	77.65	gold quality
telencephalon	UBERON:0001893	77.64	gold quality
temporal lobe	UBERON:0001871	77.27	gold quality
spinal cord	UBERON:0002240	77.18	gold quality
superior frontal gyrus	UBERON:0002661	77.13	gold quality
neocortex	UBERON:0001950	76.88	gold quality
cerebral cortex	UBERON:0000956	76.66	gold quality
frontal cortex	UBERON:0001870	76.61	gold quality
Ammon’s horn	UBERON:0001954	76.38	gold quality
tibial nerve	UBERON:0001323	76.28	gold quality
postcentral gyrus	UBERON:0002581	76.15	gold quality
primary visual cortex	UBERON:0002436	76.06	gold quality
endothelial cell	CL:0000115	75.59	silver quality
entorhinal cortex	UBERON:0002728	74.47	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6911	yes	216.24
E-MTAB-7316	yes	28.09
E-GEOD-81383	no	536.34
E-ANND-3	no	3.72

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

92 targeting SLITRK2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-4779	99.86	66.50	1583

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	slitrk2	ENSDARG00000006636
mus_musculus	Slitrk2	ENSMUSG00000036790
rattus_norvegicus	Slitrk2	ENSRNOG00000011562

Paralogs (25): SLITRK3 (ENSG00000121871), LRFN3 (ENSG00000126243), LRFN1 (ENSG00000128011), SLIT2 (ENSG00000145147), LRFN2 (ENSG00000156564), LRRC38 (ENSG00000162494), SLITRK5 (ENSG00000165300), LRFN5 (ENSG00000165379), LRTM2 (ENSG00000166159), LINGO1 (ENSG00000169783), LRRN2 (ENSG00000170382), LRRN3 (ENSG00000173114), LRFN4 (ENSG00000173621), LINGO2 (ENSG00000174482), LRRN1 (ENSG00000175928), SLITRK1 (ENSG00000178235), GP5 (ENSG00000178732), SLITRK4 (ENSG00000179542), LRRC55 (ENSG00000183908), SLIT3 (ENSG00000184347), SLITRK6 (ENSG00000184564), LRRC70 (ENSG00000186105), SLIT1 (ENSG00000187122), TLR9 (ENSG00000239732), TPBGL (ENSG00000261594)

Protein

Protein identifiers

SLIT and NTRK-like protein 2 — Q9H156 (reviewed: Q9H156)

All UniProt accessions (2): B3KTY4, Q9H156

UniProt curated annotations — full annotation on UniProt →

Function. It is involved in synaptogenesis and promotes excitatory synapse differentiation. Suppresses neurite outgrowth. Involved in the negative regulation of NTRK2.

Subunit / interactions. Interacts with PTPRD; this interaction is PTPRD splicing-dependent and may induce pre-synaptic differentiation. Interacts with NTRK2.

Subcellular location. Membrane. Cell membrane. Cell projection. Dendrite.

Tissue specificity. Expressed predominantly in the cerebral cortex of the brain but also at low levels in the spinal cord and medulla. Also expressed in some astrocytic brain tumors such as astrocytomas, oligodendrogliomas, glioblastomas, gangliogliomas and primitive neuroectodermal tumors.

Disease relevance. Intellectual developmental disorder, X-linked 111 (XLID111) [MIM:301107] A neurodevelopmental disorder characterized by moderate to severe intellectual disability, delayed development, speech delay, and neuropsychiatric and behavioral problems such as anxiety, attention deficit-hyperactivity disorder and autism spectrum disorder. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the SLITRK family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H156-1	1	yes
Q9H156-2	2

RefSeq proteins (8): NP_001137475, NP_001137476, NP_001137477, NP_001137478, NP_001137480, NP_001137481, NP_001137482, NP_115928* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000372	LRRNT	Domain
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily

Pfam: PF13855

UniProt features (52 total): sequence variant 19, repeat 12, disulfide bond 4, domain 3, topological domain 2, region of interest 2, glycosylation site 2, splice variant 2, signal peptide 1, chain 1, compositionally biased region 1, modified residue 1, transmembrane region 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H156-F1	67.16	0.26

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 756

Disulfide bonds (4): 29–35, 33–46, 220–243, 222–263

Glycosylation sites (2): 84, 421

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-388844	Receptor-type tyrosine-protein phosphatases
R-HSA-112316	Neuronal System
R-HSA-6794362	Protein-protein interactions at synapses

MSigDB gene sets: 236 (showing top): WWTAAGGC_UNKNOWN, HNF3ALPHA_Q6, GOBP_SYNAPSE_ASSEMBLY, TTTGTAG_MIR520D, GOBP_POSITIVE_REGULATION_OF_SYNAPSE_ASSEMBLY, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GGGTGGRR_PAX4_03, GOBP_POSITIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, FOXD3_01, COUP_01, NKX61_01, GOBP_CELL_CELL_ADHESION

GO Biological Process (5): axonogenesis (GO:0007409), regulation of synapse organization (GO:0050807), positive regulation of synapse assembly (GO:0051965), synaptic membrane adhesion (GO:0099560), regulation of presynapse assembly (GO:1905606)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): plasma membrane (GO:0005886), dendrite (GO:0030425), postsynaptic membrane (GO:0045211), glutamatergic synapse (GO:0098978), GABA-ergic synapse (GO:0098982), membrane (GO:0016020), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Protein-protein interactions at synapses	1
Neuronal System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
synapse organization	2
regulation of synapse assembly	2
synapse	2
cellular anatomical structure	2
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
regulation of synapse structure or activity	1
regulation of cellular component organization	1
synapse assembly	1
positive regulation of nervous system development	1
positive regulation of cell junction assembly	1
cell-cell adhesion	1
presynapse assembly	1
regulation of presynapse organization	1
binding	1
membrane	1
cell periphery	1
neuron projection	1
dendritic tree	1
synaptic membrane	1
postsynapse	1

Protein interactions and networks

STRING

1440 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLITRK2	NPTX1	Q15818	803
SLITRK2	PTPRS	Q13332	687
SLITRK2	IL1RAPL1	Q9NZN1	678
SLITRK2	TBCD	Q9BTW9	675
SLITRK2	HDC	P19113	668
SLITRK2	IMMP2L	Q96T52	647
SLITRK2	PTPRD	P23468	589
SLITRK2	PTPRO	Q16827	557
SLITRK2	FMR1NB	Q8N0W7	550
SLITRK2	SGCE	O43556	548
SLITRK2	FMR1	Q06787	545
SLITRK2	BAIAP2	Q9UQB8	511
SLITRK2	CXorf51A	A0A1B0GTR3	507
SLITRK2	NTRK1	P04629	507
SLITRK2	AFF2	P51816	507

IntAct

0 interactions, top by confidence:

BioGRID (2): SLITRK2 (Synthetic Lethality), SLITRK2 (Proximity Label-MS)

ESM2 similar proteins: A1A4H9, A2ARI4, A6NDA9, B0BLW3, B4F7C5, D3ZAL8, D3ZTV3, D4A6D8, D4A7P2, E7FE13, F1MT22, O14498, O43155, O43300, P0DM44, P83286, Q149C3, Q5NVQ6, Q5R6B1, Q5R7M3, Q5RAC4, Q6PFC5, Q6RKD8, Q80WD0, Q80XG9, Q80ZD7, Q80ZD8, Q80ZD9, Q810C0, Q810C1, Q86SJ2, Q86UE6, Q86UN2, Q86VH4, Q86VH5, Q86WK6, Q8BGA3, Q8BLU0, Q8BZ81, Q8C2S7

Diamond homologs: E9Q7T7, G5EFX6, O02678, O15335, O46390, O46403, O55226, O70210, O94933, O94991, P14770, P21809, P21810, P28653, P47853, P83503, Q27972, Q5RAC4, Q6NUI6, Q6RKD8, Q7Z2Q7, Q810B7, Q810B9, Q810C0, Q810C1, Q8C031, Q8C110, Q91009, Q96PX8, Q9GKQ6, Q9H156, Q9HCJ2, Q9NZU1, B1H234, Q5R6T0, Q8BGT1, Q9NZU0, Q7M6Z0, Q80WD1, Q810B8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

143 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	2
Uncertain significance	88
Likely benign	14
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1334906	NM_032539.5(SLITRK2):c.221T>C (p.Leu74Ser)	Likely pathogenic
1334907	NM_032539.5(SLITRK2):c.934A>G (p.Thr312Ala)	Likely pathogenic

SpliceAI

832 predictions. Top by Δscore:

Variant	Effect	Δscore
X:145818413:CAG:C	donor_loss	0.9900
X:145818414:AG:A	donor_loss	0.9900
X:145818416:GTAG:G	donor_loss	0.9900
X:145819523:T:G	donor_gain	0.9900
X:145829328:T:G	acceptor_gain	0.9700
X:145818781:G:GT	donor_gain	0.9600
X:145819213:GAAAT:G	donor_gain	0.9600
X:145819214:A:T	donor_gain	0.9600
X:145818373:GCT:G	donor_gain	0.9500
X:145818501:G:GT	donor_gain	0.9500
X:145820533:CCAGG:C	donor_loss	0.9500
X:145820534:CAG:C	donor_loss	0.9500
X:145820535:AG:A	donor_loss	0.9500
X:145820536:GG:G	donor_loss	0.9500
X:145820537:G:GA	donor_loss	0.9500
X:145820538:T:G	donor_loss	0.9500
X:145820776:C:CG	donor_gain	0.9500
X:145822380:AAG:A	acceptor_gain	0.9400
X:145819031:TCC:T	donor_gain	0.9300
X:145820472:A:AG	acceptor_gain	0.9300
X:145820473:G:GG	acceptor_gain	0.9300
X:145821883:GT:G	donor_gain	0.9300
X:145822381:A:G	acceptor_gain	0.9300
X:145829341:A:AG	acceptor_gain	0.9300
X:145818412:GCAG:G	donor_gain	0.9200
X:145821704:C:CA	acceptor_gain	0.9200
X:145818571:C:T	donor_gain	0.9100
X:145818777:A:T	donor_gain	0.9100
X:145820468:TTGCA:T	acceptor_loss	0.9100
X:145820469:TGCA:T	acceptor_loss	0.9100

AlphaMissense

5541 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:145822769:T:C	L115P	1.000
X:145822775:T:C	L117P	1.000
X:145822841:T:C	L139P	1.000
X:145822857:T:A	N144K	1.000
X:145822857:T:G	N144K	1.000
X:145822904:T:A	L160H	1.000
X:145822913:T:C	L163P	1.000
X:145822919:T:C	L165P	1.000
X:145822922:A:T	N166I	1.000
X:145822925:A:T	D167V	1.000
X:145822929:C:A	N168K	1.000
X:145822929:C:G	N168K	1.000
X:145822988:T:C	L188P	1.000
X:145822991:G:T	R189M	1.000
X:145822998:T:A	N191K	1.000
X:145822998:T:G	N191K	1.000
X:145823073:T:A	N216K	1.000
X:145823073:T:G	N216K	1.000
X:145823077:T:A	W218R	1.000
X:145823077:T:C	W218R	1.000
X:145823079:G:C	W218C	1.000
X:145823079:G:T	W218C	1.000
X:145823083:T:A	C220S	1.000
X:145823083:T:C	C220R	1.000
X:145823084:G:A	C220Y	1.000
X:145823084:G:C	C220S	1.000
X:145823085:C:G	C220W	1.000
X:145823113:T:A	W230R	1.000
X:145823113:T:C	W230R	1.000
X:145823115:G:C	W230C	1.000

dbSNP variants (sampled 300 via entrez): RS1001861008 (X:145824828 C>A,G,T), RS1001870773 (X:145825243 A>G), RS1002479083 (X:145816303 G>A), RS1002869356 (X:145826960 T>C), RS1003076670 (X:145818554 G>C), RS1004732276 (X:145822666 G>A,C), RS1005332798 (X:145825466 C>T), RS1005447188 (X:145816384 G>T), RS1005629705 (X:145825902 G>C,T), RS1005636059 (X:145816105 G>A), RS1006216314 (X:145828376 T>A), RS1006229490 (X:145818218 G>T), RS1006338948 (X:145827729 C>A,T), RS1006613353 (X:145817038 C>T), RS1006855753 (X:145818568 G>A,C)

Disease associations

OMIM: gene MIM:300561 | disease phenotypes: MIM:301107, MIM:233100

GenCC curated gene-disease

Disease	Classification	Inheritance
intellectual developmental disorder, X-linked 111	Strong	X-linked

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
X-linked complex neurodevelopmental disorder	Limited	XL

Mondo (3): intellectual disability (MONDO:0001071), intellectual developmental disorder, X-linked 111 (MONDO:0957203), familial renal glucosuria (MONDO:0009297)

Orphanet (2): Familial renal glucosuria (Orphanet:69076), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

24 total (24 of 24 shown, HPO-id order):

HPO	Term
HP:0000718	Aggressive behavior
HP:0000722	Compulsive behaviors
HP:0000729	Autistic behavior
HP:0000739	Anxiety
HP:0000750	Delayed speech and language development
HP:0000752	Hyperactivity
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001257	Spasticity
HP:0001263	Global developmental delay
HP:0001332	Dystonia
HP:0001344	Absent speech
HP:0001417	X-linked inheritance
HP:0002119	Ventriculomegaly
HP:0002317	Unsteady gait
HP:0002751	Kyphoscoliosis
HP:0003593	Infantile onset
HP:0007371	Corpus callosum atrophy
HP:0011968	Feeding difficulties
HP:0033725	Thin corpus callosum
HP:0034295	Reduced cerebral white matter volume
HP:0100021	Cerebral palsy
HP:0100035	Phonic tics
HP:0410170	Hippocampal atrophy

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST009391_1318	Metabolite levels	5.000000e-06
GCST009391_1320	Metabolite levels	7.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010519	pantothenic acid measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D006030	Glycosuria, Renal	C12.050.351.968.419.815.532; C12.050.351.968.934.363.450; C12.200.777.419.815.532; C12.200.777.934.363.450; C12.950.419.815.532; C12.950.934.363.450; C16.320.831.532; C18.452.394.937.450
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation	2
arsenite	decreases methylation	1
sodium arsenite	decreases expression	1
zinc chromate	increases expression, increases abundance	1
chromium hexavalent ion	increases abundance, increases expression	1
CGP 52608	affects binding, increases reaction	1
Gemcitabine	increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cadmium	increases abundance, increases expression	1
Folic Acid	increases expression	1
Lead	affects expression	1
Cadmium Chloride	increases abundance, increases expression	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders